TY  - JOUR
AU  - Cobo, Manuel
AU  - Rodríguez-Abreu, Delvys
AU  - Pérez Parente, Diego
AU  - Ruiz Gracia, Pedro
AU  - González, Jorge G
PY  - 2021
DO  - 10.1007/s40487-021-00139-3
UR  - https://hdl.handle.net/10668/24515
T2  - Oncology and therapy
AB  - Atezolizumab is a monoclonal antibody targeting the programmed death ligand 1 (PD-L1) that was approved in 2017 in the USA and Europe for the second-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). This review article...
LA  - en
KW  - Atezolizumab
KW  - Non-small cell lung cancer
KW  - Second-line treatment
KW  - Targeted therapy
TI  - Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review.
TY  - research article
VL  - 9
ER  -